Carfilzomib weekly 20/56 mg/m2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma

Autor:	Jean-Gabriel Fuzibet, Delphine Bauwens, Xavier Leleu, Vincent Javaugue, Florent Plasse, Niels Moya, Helene Gardeney, Sabrina Bouyier, Stéphanie Guidez, Jocelyn Barrier, Paul Franques, Emmanuel Fleck, Florence Sabirou, Valentine Richez, Laurence Legros, Cécile Gruchet, Anthony Bonnin, Guillemette Fouquet, Angela Gil, Isabelle Princet, Jeremie Diolez, Celine Dieval, Anthony Levy, Antoine Brigaud, Frank Bridoux, Hervé Avet-Loiseau, Geraldine Durand, Sylvain Primault, Antoine Machet, Claire Daras, Arthur Bobin, Isabelle Azais
Rok vydání:	2018
Předmět:	0301 basic medicine Oncology medicine.medical_specialty business.industry Salvage therapy Hematology medicine.disease Carfilzomib 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine chemistry 030220 oncology & carcinogenesis Internal medicine Relapsed refractory medicine Progression-free survival business Dexamethasone Multiple myeloma medicine.drug Lenalidomide
Zdroj:	American Journal of Hematology. 94:E17-E20
ISSN:	0361-8609
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::75a588567fef282de6c47b4056fb6b22 https://doi.org/10.1002/ajh.25327 Zobrazit plný text záznamu Plný text